![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The company is aiming to concentrate on the clinical advancement of THC:CBD (Tetrahydrocannabinol), a partial agonist of the CB1 receptor with Cannabidiol. Both controlled substances will undergo evaluation for the treatment of chemotherapy-induced neuropathic pain.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: THC:CBD
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: German Pain Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024